The Evolving Landscape of Biomarker Testing in Metastatic Colorectal Cancer (mCRC)
Daniel Ahn, DO, discusses the evolution of biomarker testing in metastatic colorectal cancer, highlighting the shift from understanding only the prognostic implications of genetic alterations to recognizing their predictive role in targeted therapies, and emphasizes the potential of circulating tumor DNA for rapid diagnosis and assessing treatment response.
EP: 1.An Overview of Colorectal Cancer (CRC)
Now Viewing
EP: 2.The Evolving Landscape of Biomarker Testing in Metastatic Colorectal Cancer (mCRC)
EP: 3.Common Testing Strategies for Molecular Markers in mCRC
EP: 4.Patient Scenario: A 65-Year-Old Man with HER2+ mCRC
EP: 5.MOUNTAINEER-01 Trial: Tucatinib in Patients With mCRC
EP: 6.DESTINY-CRC02 Trial: Trastuzumab Deruxtecan for the Management of mCRC
EP: 7.Approaches for Treatment Sequencing in Patients With HER2+ mCRC
EP: 8.Patient Scenario: A 66-Year-Old Male With BRAF-Mutant mCRC
EP: 9.The Role of BRAF in mCRC
EP: 10.BEACON Study: Encorafenib, Binimetinib, and Cetuximab in BRAF-Mutant mCRC
EP: 11.BREAKWATER Study: Encorafenib, Cetuximab, and Chemotherapy for BRAF-Mutant mCRC
EP: 12.The Future of BRAF-Mutant mCRC Management
EP: 13.Future CRC Treatment to Focus on Mutation Status, Expert Says
EP: 14.Tanios S. Bekaii-Saab, MD, Speaks to Expanding Horizons in CRC Treatment
Recent Videos
Related Content
FDA Approves Encorafenib/Cetuximab Plus mFOLFOX6 for Advanced BRAF V600E+ CRC
December 20th 2024Article
The FDA has granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.
